<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623829</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-1093</org_study_id>
    <nct_id>NCT02623829</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)</brief_title>
  <official_title>Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring: A Double Blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dermatological surgeons wear many hats to care for subjects with skin cancer. While their&#xD;
      role in cancerous tissue removal results in superior cure rates, there is also a need for&#xD;
      skilled excisional repair and effective wound healing regimens so the subject can heal with&#xD;
      the least amount of scarring necessary. As such, numerous techniques have been developed for&#xD;
      reducing the morbidity associated with excessive scarring. Various flaps and grafts allow the&#xD;
      surgeon to approximate skin texture, thickness and adnexa with respect to the residual&#xD;
      surrounding tissue. Optimal cosmetic and functional outcomes require close wound&#xD;
      approximation with minimal static tension along the wound edge. In addition, there are&#xD;
      post-operative wound care techniques that range from special dressings to cosmetic scar&#xD;
      modification. To date, most surgical wounds are allowed to heal at least partially before&#xD;
      scar revision or modulation is attempted.&#xD;
&#xD;
      Botulinum toxin presents a unique opportunity for surgeons to affect scar formation&#xD;
      throughout the duration of the healing process. These effects are likely independent and&#xD;
      adjunctive to any and all wound care techniques, and are primarily attributed to a reduction&#xD;
      in dynamic tension on the wound edges. Most importantly, botulinum toxin's one time dosing&#xD;
      requirements with respect to reduced scar formation precludes the variance inherent to&#xD;
      standard wound care practices.&#xD;
&#xD;
      Therefore, it has been proposed that for selected subjects, botulinum toxin may be a safe,&#xD;
      effective and reliable means for improved post-excisional repair outcomes. Botulinum toxin&#xD;
      has been investigated as an inhibitor of excessive, post-excisional scar formation in plastic&#xD;
      surgery and Otorhinolaryngology literature. However, these promising studies have yet to&#xD;
      combine objective assessment measures of human scar formation in a randomized controlled&#xD;
      trial. In addition, there are currently no formal studies of botulinum toxin as a&#xD;
      prophylactic against excess scarring in the dermatological literature. Fortunately, Botulinum&#xD;
      toxin dosing in the forehead for the purposes of inhibiting excessive scar formation is&#xD;
      comparable to the amount given for cosmetic purposes, which is commonplace in dermatology and&#xD;
      well-studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will attempt to assess the efficacy of Botulinum toxin as a prophylactic treatment&#xD;
      in post-excisional repairs for the purpose of preventing excess scar formation. The end&#xD;
      points will be the evaluation of each scar using the Manchester Scar Scale.&#xD;
&#xD;
      All MSS and mMSS assessments will be performed in a standardized fashion. The mMSS&#xD;
      assessments will be blinded and performed by board-certified dermatologists in the Department&#xD;
      of Dermatology, Faculty Practice Associates, Icahn School of Medicine at Mount Sinai, New&#xD;
      York City.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Manchester Scar Scale (MMSS) Score</measure>
    <time_frame>6 months</time_frame>
    <description>MMSS scores range 5-18, higher score indicates poorer health outcomes. The MMSS assesses color, texture, distortion and contour of the scar.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scar Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Visual Analog Scar Scale (VASS), full score range 0-10 higher score indicates poorer health outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Width</measure>
    <time_frame>6 months</time_frame>
    <description>Scar width at 6 months after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Post-operative Excessive Scarring</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin</intervention_name>
    <description>50 units of botulinum toxin diluted in 1ml of normal saline will be administered.</description>
    <arm_group_label>Botulinum Toxin</arm_group_label>
    <other_name>Botox,</other_name>
    <other_name>OnabotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1ml of normal saline will be administered</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English-speaking adults at least 18 years old.&#xD;
&#xD;
          -  Subjects must be scheduled for an excision of forehead skin due to any etiology, with&#xD;
             a same day, single stage closure planned as the most likely surgical repair.&#xD;
&#xD;
          -  Subjects must be able to read, sign, and understand the informed consent.&#xD;
&#xD;
          -  Subject is willing and able to participate in the study as an outpatient, making&#xD;
             several visits to the study center during the treatment and follow-up periods and to&#xD;
             comply with all study requirements including concomitant medication and other&#xD;
             treatment restrictions.&#xD;
&#xD;
          -  If subject is a female of childbearing potential she must have a negative urine&#xD;
             pregnancy test result prior to study treatment initiation and must agree to use an&#xD;
             approved method of birth control while enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with an unstable medical condition as deemed by the clinical investigator,&#xD;
             including review of the subject's prior and current medications.&#xD;
&#xD;
          -  Subjects with Myasthenia gravis, Lambert-Eaton Syndrome or other neuromuscular&#xD;
             disorder.&#xD;
&#xD;
          -  Subjects taking medications that may alter the function of neuromuscular junctions&#xD;
             (i.e. aminoglycoside antibiotics)&#xD;
&#xD;
          -  Women who are pregnant, lactating, or planning to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          -  Subjects who have a history of keloids.&#xD;
&#xD;
          -  Known allergy to botulinum toxin.&#xD;
&#xD;
          -  Subjects who are not able to be closed with a same day, single stage technique.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Michael Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jablonka EM, Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2012 Oct;28(5):525-35. doi: 10.1055/s-0032-1325641. Epub 2012 Oct 1.</citation>
    <PMID>23027220</PMID>
  </reference>
  <reference>
    <citation>Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006 Aug;81(8):1023-8.</citation>
    <PMID>16901024</PMID>
  </reference>
  <reference>
    <citation>Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000 May;105(6):1948-53; discussion 1954-5.</citation>
    <PMID>10839391</PMID>
  </reference>
  <reference>
    <citation>Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2002 Feb;18(1):35-9.</citation>
    <PMID>11823931</PMID>
  </reference>
  <reference>
    <citation>Gassner HG, Sherris DA, Friedman O. Botulinum toxin-induced immobilization of lower facial wounds. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):140-2. doi: 10.1001/archfacial.2009.3.</citation>
    <PMID>19289689</PMID>
  </reference>
  <reference>
    <citation>Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004 Nov;114(6 Suppl):1S-22S. doi: 10.1097/01.PRS.0000144795.76040.D3. Review.</citation>
    <PMID>15507786</PMID>
  </reference>
  <reference>
    <citation>Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg. 2003 May;29(5):461-7.</citation>
    <PMID>12752512</PMID>
  </reference>
  <reference>
    <citation>Zimbler MS, Nassif PS. Adjunctive applications for botulinum toxin in facial aesthetic surgery. Facial Plast Surg Clin North Am. 2003 Nov;11(4):477-82. Review.</citation>
    <PMID>15062252</PMID>
  </reference>
  <reference>
    <citation>Beausang E, Floyd H, Dunn KW, Orton CI, Ferguson MW. A new quantitative scale for clinical scar assessment. Plast Reconstr Surg. 1998 Nov;102(6):1954-61.</citation>
    <PMID>9810991</PMID>
  </reference>
  <reference>
    <citation>Duncan JAL, Bond JS, Mason T, Ludlow A, Cridland P, O'Kane S, Ferguson MWJ. Visual analogue scale scoring and ranking: a suitable and sensitive method for assessing scar quality? Plast Reconstr Surg. 2006 Sep 15;118(4):909-918. doi: 10.1097/01.prs.0000232378.88776.b0.</citation>
    <PMID>16980850</PMID>
  </reference>
  <reference>
    <citation>Durani P, McGrouther DA, Ferguson MW. Current scales for assessing human scarring: a review. J Plast Reconstr Aesthet Surg. 2009 Jun;62(6):713-20. doi: 10.1016/j.bjps.2009.01.080. Epub 2009 Mar 20. Review.</citation>
    <PMID>19303834</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <results_first_submitted>October 21, 2020</results_first_submitted>
  <results_first_submitted_qc>October 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Daniel Michael Bernstein</investigator_full_name>
    <investigator_title>Daniel Bernstein, MD</investigator_title>
  </responsible_party>
  <keyword>scar prophylaxis</keyword>
  <keyword>Botulinum Toxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02623829/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin</title>
          <description>subcutaneous injections of onabotulinumtoxinA (1 mL = 50 units) immediately following closure of forehead wounds</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>subcutaneous injections of saline (1 mL) immediately following closure of forehead wounds</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Botulinum Toxin</title>
          <description>subcutaneous injections of onabotulinumtoxinA (1 mL = 50 units) immediately following closure of forehead wounds</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>subcutaneous injections of saline (1 mL) immediately following closure of forehead wounds</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="45" upper_limit="72"/>
                    <measurement group_id="B2" value="59" lower_limit="43" upper_limit="75"/>
                    <measurement group_id="B3" value="58" lower_limit="44" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Autoimmune conditions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scar location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Median forehead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paramedian forehead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral forehead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scar length</title>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="32" upper_limit="75"/>
                    <measurement group_id="B2" value="54" lower_limit="28" upper_limit="72"/>
                    <measurement group_id="B3" value="55" lower_limit="32" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Modified Manchester Scar Scale (MMSS) Score</title>
        <description>MMSS scores range 5-18, higher score indicates poorer health outcomes. The MMSS assesses color, texture, distortion and contour of the scar.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin</title>
            <description>subcutaneous injections of onabotulinumtoxinA (1 mL = 50 units) immediately following closure of forehead wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>subcutaneous injections of saline (1 mL) immediately following closure of forehead wounds</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Manchester Scar Scale (MMSS) Score</title>
          <description>MMSS scores range 5-18, higher score indicates poorer health outcomes. The MMSS assesses color, texture, distortion and contour of the scar.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scar Scale</title>
        <description>Visual Analog Scar Scale (VASS), full score range 0-10 higher score indicates poorer health outcomes</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin</title>
            <description>subcutaneous injections of onabotulinumtoxinA (1 mL = 50 units) immediately following closure of forehead wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>subcutaneous injections of saline (1 mL) immediately following closure of forehead wounds</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scar Scale</title>
          <description>Visual Analog Scar Scale (VASS), full score range 0-10 higher score indicates poorer health outcomes</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scar Width</title>
        <description>Scar width at 6 months after treatment</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin</title>
            <description>subcutaneous injections of onabotulinumtoxinA (1 mL = 50 units) immediately following closure of forehead wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>subcutaneous injections of saline (1 mL) immediately following closure of forehead wounds</description>
          </group>
        </group_list>
        <measure>
          <title>Scar Width</title>
          <description>Scar width at 6 months after treatment</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.8" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Botulinum Toxin</title>
          <description>subcutaneous injections of onabotulinumtoxinA (1 mL = 50 units) immediately following closure of forehead wounds</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>subcutaneous injections of saline (1 mL) immediately following closure of forehead wounds</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>mild unilateral eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Bernstein</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-731-3311</phone>
      <email>daniel.bernstein@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

